Type 1 diabetes TrialNet - An international collaborative clinical trials network

Jay S Skyler, Carla J. Greenbaum, John M. Lachin, Ellen Leschek, Lisa Rafkin, Peter Savage, Lisa Spain

Research output: Chapter in Book/Report/Conference proceedingConference contribution

70 Citations (Scopus)

Abstract

Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the prevention or delay of type 1 diabetes (T1D). The fundamental goal of TrialNet is to counter the T1D disease process by immune modulation and/or enhancement of β cell proliferation and regeneration. To achieve this goal, TrialNet researchers are working to better understand the natural history of the disease, to identify persons at risk, and to clinically evaluate novel therapies that balance potential risks and benefits. The particular focus is on studies of preventive measures. In addition, TrialNet evaluates therapies in individuals with newly diagnosed T1D with preserved β cell function to help determine the risk/benefit profile and gain an initial assessment of potential efficacy in preservation of β cell function, so that promising agents can be studied in prevention trials. In addition, TrialNet evaluates methodologies that enhance the conduct of its clinical trials, which includes tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies laying the foundation for future clinical trials.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages14-24
Number of pages11
Volume1150
DOIs
StatePublished - Dec 1 2008

Publication series

NameAnnals of the New York Academy of Sciences
Volume1150
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Medical problems
Type 1 Diabetes Mellitus
Clinical Trials
Immune System Diseases
Cell proliferation
Regeneration
Biomarkers
Research Personnel
Cell Proliferation
Modulation
Outcome Assessment (Health Care)
Therapeutics
Research

Keywords

  • Clinical trials
  • Immunomodulation
  • Network
  • Prevention
  • Type 1 diabetes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Skyler, J. S., Greenbaum, C. J., Lachin, J. M., Leschek, E., Rafkin, L., Savage, P., & Spain, L. (2008). Type 1 diabetes TrialNet - An international collaborative clinical trials network. In Annals of the New York Academy of Sciences (Vol. 1150, pp. 14-24). (Annals of the New York Academy of Sciences; Vol. 1150). https://doi.org/10.1196/annals.1447.054

Type 1 diabetes TrialNet - An international collaborative clinical trials network. / Skyler, Jay S; Greenbaum, Carla J.; Lachin, John M.; Leschek, Ellen; Rafkin, Lisa; Savage, Peter; Spain, Lisa.

Annals of the New York Academy of Sciences. Vol. 1150 2008. p. 14-24 (Annals of the New York Academy of Sciences; Vol. 1150).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Skyler, JS, Greenbaum, CJ, Lachin, JM, Leschek, E, Rafkin, L, Savage, P & Spain, L 2008, Type 1 diabetes TrialNet - An international collaborative clinical trials network. in Annals of the New York Academy of Sciences. vol. 1150, Annals of the New York Academy of Sciences, vol. 1150, pp. 14-24. https://doi.org/10.1196/annals.1447.054
Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin L, Savage P et al. Type 1 diabetes TrialNet - An international collaborative clinical trials network. In Annals of the New York Academy of Sciences. Vol. 1150. 2008. p. 14-24. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1447.054
Skyler, Jay S ; Greenbaum, Carla J. ; Lachin, John M. ; Leschek, Ellen ; Rafkin, Lisa ; Savage, Peter ; Spain, Lisa. / Type 1 diabetes TrialNet - An international collaborative clinical trials network. Annals of the New York Academy of Sciences. Vol. 1150 2008. pp. 14-24 (Annals of the New York Academy of Sciences).
@inproceedings{c8e1435fc9904c168206e7759a8183e8,
title = "Type 1 diabetes TrialNet - An international collaborative clinical trials network",
abstract = "Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the prevention or delay of type 1 diabetes (T1D). The fundamental goal of TrialNet is to counter the T1D disease process by immune modulation and/or enhancement of β cell proliferation and regeneration. To achieve this goal, TrialNet researchers are working to better understand the natural history of the disease, to identify persons at risk, and to clinically evaluate novel therapies that balance potential risks and benefits. The particular focus is on studies of preventive measures. In addition, TrialNet evaluates therapies in individuals with newly diagnosed T1D with preserved β cell function to help determine the risk/benefit profile and gain an initial assessment of potential efficacy in preservation of β cell function, so that promising agents can be studied in prevention trials. In addition, TrialNet evaluates methodologies that enhance the conduct of its clinical trials, which includes tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies laying the foundation for future clinical trials.",
keywords = "Clinical trials, Immunomodulation, Network, Prevention, Type 1 diabetes",
author = "Skyler, {Jay S} and Greenbaum, {Carla J.} and Lachin, {John M.} and Ellen Leschek and Lisa Rafkin and Peter Savage and Lisa Spain",
year = "2008",
month = "12",
day = "1",
doi = "10.1196/annals.1447.054",
language = "English",
isbn = "9781573317337",
volume = "1150",
series = "Annals of the New York Academy of Sciences",
pages = "14--24",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Type 1 diabetes TrialNet - An international collaborative clinical trials network

AU - Skyler, Jay S

AU - Greenbaum, Carla J.

AU - Lachin, John M.

AU - Leschek, Ellen

AU - Rafkin, Lisa

AU - Savage, Peter

AU - Spain, Lisa

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the prevention or delay of type 1 diabetes (T1D). The fundamental goal of TrialNet is to counter the T1D disease process by immune modulation and/or enhancement of β cell proliferation and regeneration. To achieve this goal, TrialNet researchers are working to better understand the natural history of the disease, to identify persons at risk, and to clinically evaluate novel therapies that balance potential risks and benefits. The particular focus is on studies of preventive measures. In addition, TrialNet evaluates therapies in individuals with newly diagnosed T1D with preserved β cell function to help determine the risk/benefit profile and gain an initial assessment of potential efficacy in preservation of β cell function, so that promising agents can be studied in prevention trials. In addition, TrialNet evaluates methodologies that enhance the conduct of its clinical trials, which includes tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies laying the foundation for future clinical trials.

AB - Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the prevention or delay of type 1 diabetes (T1D). The fundamental goal of TrialNet is to counter the T1D disease process by immune modulation and/or enhancement of β cell proliferation and regeneration. To achieve this goal, TrialNet researchers are working to better understand the natural history of the disease, to identify persons at risk, and to clinically evaluate novel therapies that balance potential risks and benefits. The particular focus is on studies of preventive measures. In addition, TrialNet evaluates therapies in individuals with newly diagnosed T1D with preserved β cell function to help determine the risk/benefit profile and gain an initial assessment of potential efficacy in preservation of β cell function, so that promising agents can be studied in prevention trials. In addition, TrialNet evaluates methodologies that enhance the conduct of its clinical trials, which includes tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies laying the foundation for future clinical trials.

KW - Clinical trials

KW - Immunomodulation

KW - Network

KW - Prevention

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=57749176852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749176852&partnerID=8YFLogxK

U2 - 10.1196/annals.1447.054

DO - 10.1196/annals.1447.054

M3 - Conference contribution

C2 - 19120262

AN - SCOPUS:57749176852

SN - 9781573317337

VL - 1150

T3 - Annals of the New York Academy of Sciences

SP - 14

EP - 24

BT - Annals of the New York Academy of Sciences

ER -